CDMOs that routinely handle highly potent compounds must raise the bar for containment, safety, and industrial hygiene. Diverse capabilities across chemistries, purification technologies, and analytical techniques — combined with the ability to support projects seamlessly from discovery to commercial production — speed the development of complex and unstable highly potent active pharmaceutical ingredients (APIs) and their formulation into safe, approved, high-quality medicines.Read article
Ready to move from idea to impact?
Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.Contact Us
More from Curia
Lyophilization: Protecting and preserving biologics
Lyophilization, also known as freeze-drying, is often a crucial step in the manufacturing process of biologics drug products. Biologics are large, complex molecules used to treat various diseases, including cancer, autoimmune disorders, and rare gene...
Rapid discovery and characterization of monoclonal antibodies against the SARS-CoV-2 Delta spike protein
In the fall of 2021, the Delta variant of SARS-CoV-2 was the dominant strain in the US, being both more contagious than previous variants and more likely to lead to “long COVID” than subsequent Omicron variants. Here we describe the discovery and...